Drug profile

The FDA adverse-event record for Dapp + L4

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Dapp + L4. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
5.9%
death-coded share
Dog
most-reported species
5
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
1
Deaths Reported
5.9%
Death Rate

Active Ingredients

Dapp + L4

Administration Routes

UnknownSubcutaneous

Species Affected

Dog 17

Most Affected Breeds

Bulldog - French 3
Terrier - Bull - American Pit 3
Terrier - Yorkshire 2
Papillon - Spaniel - Continental Toy (with erect ears or with dropped ears (Phaléne)) 1
Crossbred Canine/dog 1
Akita 1
Beagle 1
Retriever (unspecified) 1
Terrier (unspecified) 1
Retriever - Labrador 1

Most Reported Reactions

Vomiting 5
Lethargy (see also Central nervous system depression in Neurological) 4
Anaphylaxis 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Not eating 3
Erythema (for urticaria see Immune SOC) 3
Low platelet count 2
Stiffness NOS 2
Hives (see also 'Skin') 2
Elevated alanine aminotransferase (ALT) 2
Heavy breathing 2
Bloody diarrhoea 2

Outcome Breakdown

Ongoing
9 (52.9%)
Recovered/Normal
6 (35.3%)
Euthanized
1 (5.9%)
Outcome Unknown
1 (5.9%)

Dapp + L4 Adverse Event Insights

17 reports name Dapp + L4; 1 recorded a death outcome (5.9% of reported events, not a population-level mortality rate). Active ingredient: Dapp + L4. Administration routes: Unknown, Subcutaneous.

By species: Dog (17 reports). By breed: Bulldog - French (3), Terrier - Bull - American Pit (3), Terrier - Yorkshire (2).

Leading clinical signs: Vomiting (5), Lethargy (see also Central nervous system depression in Neurological) (4), Anaphylaxis (4), Lethargy (see also Central nervous system depression in 'Neurological') (3). Outcome, 17 coded reports: Ongoing leads at 52.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.